Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.
Actively Recruiting
Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are evaluating different dose levels of Brenipatide in adults with moderate-to-severe Chronic Obstructive Pulmonary Disease COPD. The study aims to assess the safety and effectiveness of Brenipatide compared to a placebo over approximately one year. This Phase 2 trial focuses on how the drug works alongside standard care in people with COPD who have a history of smoking and recent exacerbations. Participants are randomly assigned to receive either a low dose or high dose of Brenipatide or a placebo, all given by subcutaneous injection. All groups continue their standard care therapy, which may include long-acting bronchodilators or inhaled corticosteroids. The treatment period lasts 52 weeks, during which participants receive the study drug or placebo alongside their regular medications. Throughout the study, participants will have lung function tests measuring forced expiratory volume FEV1 before bronchodilator use at baseline and at several weeks up to week 52. Researchers will also monitor COPD exacerbation rates and quality of life using specific questionnaires. Safety and treatment effects are assessed regularly to understand how Brenipatide performs in managing COPD symptoms and lung function over one year.
Actively Recruiting
Researchers are studying brenipatide LY3537031 to evaluate its safety, side effects, and effectiveness in adults with Irritable Bowel Syndrome-Constipation IBS-C. The study compares brenipatide given by injection under the skin to a placebo in a phase 2 clinical trial. Participants must meet specific IBS-C criteria and have significant abdominal pain to join. Participants receive the study drug or placebo through subcutaneous injection. The trial lasts about 36 weeks, with treatment and monitoring occurring during this period. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants will keep a daily diary to track symptoms like abdominal pain and bowel movements. Researchers will measure the percentage of weeks participants respond to treatment based on clinical criteria between weeks 9 and 16. Safety and side effects will also be closely monitored throughout the trial.
Actively Recruiting
Researchers are evaluating the safety, side effects, and effectiveness of brenipatide LY3537031 in adults with Irritable Bowel Syndrome-Diarrhea IBS-D. This study compares brenipatide given under the skin to a placebo and aims to understand how well the drug is tolerated and how it impacts symptoms in participants aged 18 to 75. The trial is a randomized, double-blind, placebo-controlled Phase 2 study sponsored by Eli Lilly and Company. Participants receive either brenipatide or placebo, both administered subcutaneously. The study follows a parallel design where different groups receive either the experimental drug or the placebo. Treatment and evaluation last approximately 36 weeks, with key outcome measurements focused on symptom responses between weeks 9 to 16 and up to week 24. During the study, participants will record symptoms daily in an electronic diary, including abdominal pain and stool consistency. Researchers will monitor safety, side effects, and symptom changes through these reports and scheduled assessments. The main outcome is the percentage of days participants show significant symptom improvement during the critical weeks of treatment. The study includes a full follow-up period to assess lasting effects and safety throughout the 36 weeks.
Actively Recruiting
Researchers are evaluating the drug brenipatide compared to a placebo to see if it works and is safe for adults with Alcohol Use Disorder AUD and hazardous alcohol use. This phase 3 study aims to understand how brenipatide affects drinking patterns over time. Participation in this trial will last about 56 weeks, with careful monitoring throughout. Participants will receive brenipatide or placebo through subcutaneous injections. The study includes escalating doses of brenipatide administered under the skin. Participants must self-inject the study drug or receive assistance from a trained support person if needed. The treatment phase is structured in parallel groups, comparing the drug against placebo. During the study, participants will attend regular visits and be asked to maintain study diaries and complete questionnaires. Researchers will assess changes in drinking patterns using the Timeline Followback Method, daily alcohol consumption, alcohol cravings, and health outcomes such as body weight and quality of life. Blood samples will be collected to measure brenipatide levels and monitor for any immune responses. The study includes safety monitoring and lasts for approximately 56 weeks.
Actively Recruiting
Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with type 2 diabetes mellitus T2DM who have an increased cardiovascular risk. This study focuses on patients whose diabetes is not adequately controlled with lifestyle changes or stable glucose-lowering medications. The trial is a Phase III, randomized, open-label, parallel-group study sponsored by AstraZeneca. Participants will be randomly assigned to receive either elecoglipron or semaglutide, both administered orally once daily at specified doses. The treatment period lasts up to 52 weeks, during which the effects of these medications on blood sugar control and other health measures will be assessed. Throughout the study, participants will undergo regular evaluations including measurements of hemoglobin A1c HbA1c, body weight, and blood pressure at baseline and at 52 weeks. Researchers will monitor changes in these parameters to assess the impact of the treatments. Safety and tolerability will also be closely followed during the trial period.
1-10 of 13
1